Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vir Biotechnology Inc V.VIR


Primary Symbol: VIR

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.


NDAQ:VIR - Post by User

Post by PaperStackson Mar 23, 2020 12:48pm
175 Views
Post# 30838036

NWT? Who cares?! Where are the financials?!?!?

NWT? Who cares?! Where are the financials?!?!? Another garbage press release from EXP, adding the lowest populated region in Canada to its channel is not material. Why can’t they provide any financial data? The last time we saw anything was Oct 29, 2019, 146 days ago! Must mean the 2019 results and Q1 are total trash, just like this company and those running it. 
Thanks for the reminder that you can’t close any deals, including the non-binding LOI with QC which stated shipments of capsules to start in Q4 2019. What happened to that? Still can’t sell oil products hey? Or the $8m in financing, why hasn’t that closed? One has to assume DD was the reason, i.e. Trichome ran away after looking under teh hood. Why would this even be needed if they had over $8m in cash as per the last financial report? Nothing makes sense with this company, but the current share price reflects where this is heading, to zero! 

<< Previous
Bullboard Posts
Next >>